+22,327.1%
ADBE vs GSK
+1,705.8%
+20,621.2%
-79.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.7% | -1.9% | -4.8% | -6.0% |
| 7D | -8.6% | -1.8% | -6.7% | -7.9% |
| 30D | +2.8% | -2.2% | +4.9% | +3.6% |
| 3M | +3.1% | -1.8% | +4.9% | +3.7% |
| 6M | -2.4% | -10.6% | +8.2% | +1.1% |
| YTD | -23.9% | +4.4% | -28.3% | -26.0% |
| 1Y | -22.6% | +30.4% | -53.0% | -31.6% |
| 3Y | -52.7% | +60.1% | -112.7% | -62.4% |
| 5Y | -60.0% | +46.8% | -106.8% | -67.6% |
| 10Y | +157.3% | +79.2% | +78.1% | +90.3% |
| All | +22,327.1% | +1,705.8% | +20,621.2% | +4,492.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling